Journal Mobile Options
Table of Contents
Vol. 6, No. 3, 1993
Issue release date: 1993
Skin Pharmacol 1993;6:187–192
(DOI:10.1159/000211134)

Comparison of the Bioactivity of Mometasone Furoate 0.1% Fatty Cream, Betamethasone Dipropionate 0.05% Cream and Betamethasone Valerate 0.1% Cream in Humans

Inhibition of UV-B-lnduced Inflammation Monitored by Laser Doppler Blood Flowmetry

Bjerring P.
Department of Dermatology, University of Aarhus, Denmark

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The bioactivity of a novel topical glucocorticosteroid, mometasone furoate 0.1 % fatty cream was compared with betamethasone dipropionate 0.05% cream and betametasone valerate 0.1% cream. An ultraviolet light (UV-B)-induced inflammation assay in humans was used, and the combined effect of a single, open application of the corticosteroids was evaluated. Reduction of UV-B induced inflammation was monitored by laser Doppler blood flowmetry, clinical skin scoring and skin reflectance spectrophotometry. Skin scoring and reflectance spectrophotometry were found unsuitable because one of the cream vehicles contained titanium dioxide which shielded skin erythema. Laser Doppler blood flowmetry showed that mometasone furoate 0.1 % fatty cream was more than twofold better in reducing UV-B-induced inflammation than betamethasone dipropionate 0.05% cream and betametasone valerate 0.1 % cream, and that the effect was sustained for at least 24 h after a single application.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50